Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

This study is testing a combination of an immunotherapy drug (pembrolizumab) and a single chemotherapy drug as a first treatment option for people with advanced lung cancer who are too frail for aggressive standard chemotherapy. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with non-small cell lung cancer (NSCLC) - Your cancer is at an advanced stage (IIIc or IV) - You have a moderate level of physical limitation (ECOG performance status 2 — meaning you can care for yourself but cannot do physical work) - Standard aggressive chemotherapy is not an option for you or you have declined it - Your blood counts, kidney, and liver function meet minimum requirements **You may NOT be eligible if...** - You have active autoimmune disease (some exceptions apply) - You are on significant doses of immune-suppressing medications like steroids - You have serious heart, liver, or kidney disease - You are pregnant or breastfeeding - You are currently enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.